- Disease: Monkeypox virus infection
- Study type: Observational Cohort Study
- Study type descriptors: Prospective, Single centre
- Study aim: To evaluate the immunogenicity, in terms of the humoral and cellular immune response, and reactogenicity according to previous smallpox vaccination and HIV infection, after the administration of MVA-BN delivered as pre-exposure prophylaxis to high-risk groups by a vaccination program of an Italian Region during the 2022 mpox outbreak
- Number of participants enrolled: 164
- Study enrolling from to
Study Data
- Adults
- Fragile population
- People living with HIV
- PrEP users
- Hospital wide
- Outpatient clinic
- Infectious diseases unit
- Monkeypox virus
- Monkeypox virus infection
- Blood sample
- Pharmacological intervention
- Vaccination
- MVA-BN
External Links
Other information
Funders:
- Italian Ministry of Health “Ricerca corrente Linea 1 e 2”
- National Institute for Infectious Disease Lazzaro Spallanzani IRCCS “Advanced grant 5 × 1000, 2021”
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to